Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
November 06, 2018 16:02 ET
|
Paratek Pharmaceuticals
--NUZYRA™ (omadacycline) approved by FDA for the treatment of CABP and ABSSSI -- -- SEYSARA™ (sarecycline) approved by FDA for the treatment of moderate to severe acne vulgaris -- -- Company...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 01, 2018 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018
October 26, 2018 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline
October 04, 2018 16:01 ET
|
Paratek Pharmaceuticals
-- MAA submission for both community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) -- -- EMA decision expected second half of 2019 -- BOSTON,...
Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018
October 03, 2018 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)
October 02, 2018 18:37 ET
|
Paratek Pharmaceuticals
– Modernized Tetracycline for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) specifically designed to overcome tetracycline...
FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne
October 02, 2018 08:45 ET
|
Paratek Pharmaceuticals
– To be launched in U.S. by Almirall SA – Paratek earns $12 million milestone payment BOSTON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 01, 2018 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018
September 25, 2018 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that new data from its omadacycline clinical and microbiology programs will be presented at...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 04, 2018 16:30 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...